abs108.txt	background		trc105	is	an	igg1	endoglin	monoclonal	antibody	that	potentiates	vegfinhibitors	in	preclinical	models		we	assessed	safety		pharmacokinetics		andantitumor	activity	of	trc105	in	combination	with	axitinib	in	patients	withmetastatic	renal	cell	carcinoma	(mrcc)	subjects		materials		and	methods		heavily	pretreated	mrcc	patients	were	treatedwith	trc105	weekly	(8	mg/kg	and	then	10	mg/kg)	in	combination	with	axitinib(initially	at	5	mg	b	i	d		and	then	escalated	per	patient	tolerance	to	a	maximumof	10	mg	b	i	d	)	until	disease	progression	or	unacceptable	toxicity	using	astandard	3	+	3	phase	i	design	results		eighteen	patients	(median	number	of	prior	therapies	=	3)	were	treated	trc105	dose	escalation	proceeded	to	10	mg/kg	weekly	without	dose-limitingtoxicity		adverse	event	characteristics	of	each	drug	were	not	increased	infrequency	or	severity	when	the	two	drugs	were	administered	concurrently		trc105and	axitinib	demonstrated	preliminary	evidence	of	activity		including	partialresponses	(pr)	by	recist	in	29%	of	patients		and	median	progression-free	survival(11	3	months)		none	of	the	patients	with	pr	had	pr	to	prior	first-line	treatment	lower	baseline	levels	of	osteopontin	and	higher	baseline	levels	of	tgf-Î²	receptor3	correlated	with	overall	response	rate	conclusion		trc105	at	8	and	10	mg/kg	weekly	was	well	tolerated	in	combinationwith	axitinib		with	encouraging	evidence	of	activity	in	patients	with	mrcc		amulticenter		randomized	phase	ii	trial	of	trc105	and	axitinib	has	recentlycompleted	enrollment	(nct01806064)	implications	for	practice		trc105	is	a	monoclonal	antibody	to	endoglin	(cd105)		areceptor	densely	expressed	on	proliferating	endothelial	cells	and	also	on	renalcancer	stem	cells	that	is	implicated	as	a	mediator	of	resistance	to	inhibitors	ofthe	vegf	pathway		in	this	phase	i	trial		trc105	combined	safely	with	axitinib	atthe	recommended	single	agent	doses	of	each	drug	in	patients	with	renal	cellcarcinoma		the	combination	demonstrated	durable	activity	in	a	vegfinhibitor-refractory	population	and	modulated	several	angiogenic	biomarkers		arandomized	phase	ii	trial	testing	trc105	in	combination	with	axitinib	in	clearcell	renal	cell	carcinoma	has	completed	accrual	
